Internal Medicine, Rheumatology · Rochester Hills, MI
NPI
1558329359
Since 2006
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
3
Medicare group memberships
Hospitals
5
Hospital affiliations
1701 South Blvd E Ste 110
Rochester Hills, MI, 48307
Phone (248) 853-0803
Groups this clinician bills Medicare through
Medicare paid, 2024
$600K
53,863 services
Medicare patients, 2024
264
Average age 75
Drug cost, 2024
$1.9M
3,650 prescriptions
Company payments, 2025
$3,476
From 17 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by John E Tower was code J1602 (injection, golimumab, 1 mg, for intravenous use), 15,300 times for 17 patients. In total John E Tower billed 53,863 services in 30 codes, and Medicare paid $600K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-12-03.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 15,300 | 17 | $9.13 | $140K |
| J0897 Injection, denosumab, 1 mg | Office | 3,240 | 31 | $20.55 | $67K |
| 99214 Office E&M - Established | Office | 464 | 247 | $89.60 | $42K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 288 | 31 | $0.07 | $20.88 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 226 | 163 | $11.18 | $2,526 |
| 96413 Chemotherapy Administration | Office | 217 | 30 | $93.37 | $20K |
| 20610 Joint Injection | Office | 82 | 42 | $50.28 | $4,123 |
| 96401 Chemotherapy Administration | Office | 72 | 32 | $54.51 | $3,924 |
| 99213 Office E&M - Established | Office | 36 | 18 | $66.13 | $2,381 |
By year: 2022 $512K for 33,742 services; 2023 $627K for 49,070 services; 2024 $600K for 53,863 services.
Medicare prescription drug claims, 2024
In 2024, the drug John E Tower prescribed most often to Medicare patients was Gabapentin, with 501 prescriptions and refills. In total John E Tower wrote 3,650 Medicare prescriptions that cost $1.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Gabapentin Generic | 501 | 1,218 | 141 | $7,713 |
| Prednisone Generic | 413 | 722 | 159 | $3,456 |
| Hydroxychloroquine Sulfate Generic | 357 | 976 | 101 | $26K |
| Methotrexate Methotrexate Sodium | 303 | 799 | 93 | $12K |
| Tramadol Hcl Generic | 251 | 253 | 53 | $1,700 |
| Meloxicam Generic | 249 | 627 | 71 | $1,606 |
| Sulfasalazine Generic | 186 | 528 | 61 | $6,959 |
| Celecoxib Generic | 186 | 478 | 68 | $7,939 |
| Tramadol Hcl-Acetaminophen Tramadol Hcl/Acetaminophen | 121 | 122 | 36 | $4,338 |
| Pregabalin Generic | 94 | 221 | 22 | $4,645 |
| Diclofenac Sodium Generic | 84 | 110 | 40 | $2,069 |
| Leflunomide Generic | 67 | 171 | 19 | $6,216 |
| Enbrel Sureclick Etanercept | 62 | 67 | Under 11 | $496K |
| Alendronate Sodium Generic | 54 | 140 | 16 | $518 |
| Omeprazole Generic | 44 | 122 | 16 | $701 |
Brand drugs: 452 claims; generic drugs: 3,198 claims; opioid claims: 412.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid John E Tower $3,476 ($3,476 in general payments such as food, travel and fees) from 17 companies. The largest payer was Amgen Inc. with $1,097.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 61 | $1,097 |
| Janssen Biotech, Inc. JNJ | 20 | $504 |
| Abbvie Inc. ABBV | 27 | $493 |
| UCB, Inc. UCB.BR | 6 | $271 |
| Novartis Pharmaceuticals Corporation NVS | 10 | $226 |
| E.R. Squibb & Sons, L.L.C. BMY | 28 | $221 |
| Genzyme Corporation SNY | 5 | $215 |
| GlaxoSmithKline, LLC. GSK | 4 | $184 |
| Sandoz Inc. SDZ.SW | 2 | $52 |
| Aurinia Pharma U.S., Inc. AUPH | 2 | $47.31 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.